InSilicoTrials, Axoltis Pharma Announce Neurological Therapy Collaboration

InSilicoTrials, an artificial intelligence (AI) and simulation tools provider for drug development, and Axoltis, a biopharma company, have announced a partnership focused on optimizing the clinical development plan of Axoltis' drug candidate, NX210c. By implementing the InSilicoNeuro suite, which includes a variation of CNS models, the organizations will assess the impact of Axoltis' drug candidate on virtual patients with different conditions, including Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease and Multiple sclerosis (MS).

"We are thrilled to collaborate with Axoltis in our shared mission to advance therapeutic solutions for neurological disorders," said Luca Emili, CEO of InSilicoTrials. "This partnership represents an exciting synergy between cutting-edge simulation technologies and innovative biotechnological advancements. Together, we aim to unlock new insights and develop groundbreaking treatments that will positively impact the lives of patients with neurologic impairments worldwide."

Reference: InSilicoTrials and Axoltis Pharma Collaborate to Advance Therapeutic Solutions for Neurological Disorders. PR Newswire. July 27, 2023. Accessed July 28, 2023. https://www.prnewswire.com/news-releases/insilicotrials-and-axoltis-pharma-collaborate-to-advance-therapeutic-solutions-for-neurological-disorders-301886789.html